Hepatic copper storage disease causes progressive liver damage and welfare harm in susceptible breeds. Dietary management and chelation therapy significantly improve outcomes.
Copper storage disease causes progressive, insidious liver damage that may not be apparent until significant hepatic reserve is lost. Clinical hepatic disease causes profound welfare harm — jaundice, nausea, vomiting, neurological signs from hepatic encephalopathy, and the discomfort of ascites (abdominal fluid accumulation) all represent significant suffering. Early diagnosis before clinical disease provides the greatest welfare benefit by enabling treatment before irreversible damage accumulates.
The welfare story is positive in diagnosed cases. Penicillamine chelation therapy mobilizes and removes hepatic copper effectively, and many dogs show dramatic clinical improvement within months of starting treatment. Dietary management — low-copper diets avoiding shellfish, organ meats, and copper-supplemented foods — reduces ongoing accumulation. Dogs with early disease treated proactively can have normal or near-normal life expectancies.
For Bedlington Terriers, DNA testing for the COMMD1 gene mutation allows identification of affected, carrier, and clear dogs. Responsible breeding programs select against the affected genotype, reducing disease prevalence. This represents a welfare benefit at the population level that complements individual case management.